{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:01:39Z","timestamp":1794322899329,"version":"4.9.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:p>\n                    Mitochondria are a major site of reactive oxygen species production, which may contribute to the development of cardiovascular disease. Protecting mitochondria from oxidative damage should be an effective therapeutic strategy; however, conventional antioxidants are ineffective, because they cannot penetrate the mitochondria. This study investigated the role of mitochondrial oxidative stress during development of hypertension in the stroke-prone spontaneously hypertensive rat, using the mitochondria-targeted antioxidant, MitoQ\n                    <jats:sub>10<\/jats:sub>\n                    . Eight-week\u2013old male stroke-prone spontaneously hypertensive rats were treated with MitoQ\n                    <jats:sub>10<\/jats:sub>\n                    (500 \u03bcmol\/L; n=16), control compound decyltriphenylphosphonium (decylTPP; 500 \u03bcmol\/L; n=8), or vehicle (n=9) in drinking water for 8 weeks. Systolic blood pressure was significantly reduced by \u224825 mm Hg over the 8-week MitoQ\n                    <jats:sub>10<\/jats:sub>\n                    treatment period compared with decylTPP (F=5.94;\n                    <jats:italic>P<\/jats:italic>\n                    =0.029) or untreated controls (F=65.6;\n                    <jats:italic>P<\/jats:italic>\n                    =0.0001). MitoQ\n                    <jats:sub>10<\/jats:sub>\n                    treatment significantly improved thoracic aorta NO bioavailability (1.16\u00b10.03 g\/g;\n                    <jats:italic>P<\/jats:italic>\n                    =0.002, area under the curve) compared with both untreated controls (0.68\u00b10.02 g\/g) and decylTPP-treated rats (0.60\u00b10.06 g\/g). Cardiac hypertrophy was significantly reduced by MitoQ\n                    <jats:sub>10<\/jats:sub>\n                    treatment compared with untreated control and decylTPP treatment (MitoQ\n                    <jats:sub>10<\/jats:sub>\n                    : 4.01\u00b10.05 mg\/g; control: 4.42\u00b10.11 mg\/g; and decylTPP: 4.40\u00b10.09 mg\/g; ANOVA\n                    <jats:italic>P<\/jats:italic>\n                    =0.002). Total MitoQ\n                    <jats:sub>10<\/jats:sub>\n                    content was measured in liver, heart, carotid artery, and kidney harvested from MitoQ\n                    <jats:sub>10<\/jats:sub>\n                    -treated rats by liquid chromatography-tandem mass spectrometry. All of the organs analyzed demonstrated detectable levels of MitoQ\n                    <jats:sub>10<\/jats:sub>\n                    , with comparable accumulation in vascular and cardiac tissues. Administration of the mitochondria-targeted antioxidant MitoQ\n                    <jats:sub>10<\/jats:sub>\n                    protects against the development of hypertension, improves endothelial function, and reduces cardiac hypertrophy in young stroke-prone spontaneously hypertensive rats. MitoQ\n                    <jats:sub>10<\/jats:sub>\n                    provides a novel approach to attenuate mitochondrial-specific oxidative damage with the potential to become a new therapeutic intervention in human cardiovascular disease.\n                  <\/jats:p>","DOI":"10.1161\/hypertensionaha.109.130351","type":"journal-article","created":{"date-parts":[[2009,7,6]],"date-time":"2009-07-06T21:53:40Z","timestamp":1246917220000},"page":"322-328","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":337,"title":["Mitochondria-Targeted Antioxidant MitoQ\n                    <sub>10<\/sub>\n                    Improves Endothelial Function and Attenuates Cardiac Hypertrophy"],"prefix":"10.1161","volume":"54","author":[{"given":"Delyth","family":"Graham","sequence":"first","affiliation":[{"name":"From the British Heart Foundation Glasgow Cardiovascular Research Centre (D.G., N.N.H., C.A.H., E.B., A.F.D.), Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom; Department of Chemistry (R.A.J.S.), University of Otago, Dunedin, New Zealand; Medical Research Council Mitochondrial Biology Unit (H.M.C., M.P.M.), Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngan N.","family":"Huynh","sequence":"additional","affiliation":[{"name":"From the British Heart Foundation Glasgow Cardiovascular Research Centre (D.G., N.N.H., C.A.H., E.B., A.F.D.), Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom; Department of Chemistry (R.A.J.S.), University of Otago, Dunedin, New Zealand; Medical Research Council Mitochondrial Biology Unit (H.M.C., M.P.M.), Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlene A.","family":"Hamilton","sequence":"additional","affiliation":[{"name":"From the British Heart Foundation Glasgow Cardiovascular Research Centre (D.G., N.N.H., C.A.H., E.B., A.F.D.), Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom; Department of Chemistry (R.A.J.S.), University of Otago, Dunedin, New Zealand; Medical Research Council Mitochondrial Biology Unit (H.M.C., M.P.M.), Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Beattie","sequence":"additional","affiliation":[{"name":"From the British Heart Foundation Glasgow Cardiovascular Research Centre (D.G., N.N.H., C.A.H., E.B., A.F.D.), Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom; Department of Chemistry (R.A.J.S.), University of Otago, Dunedin, New Zealand; Medical Research Council Mitochondrial Biology Unit (H.M.C., M.P.M.), Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin A.J.","family":"Smith","sequence":"additional","affiliation":[{"name":"From the British Heart Foundation Glasgow Cardiovascular Research Centre (D.G., N.N.H., C.A.H., E.B., A.F.D.), Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom; Department of Chemistry (R.A.J.S.), University of Otago, Dunedin, New Zealand; Medical Research Council Mitochondrial Biology Unit (H.M.C., M.P.M.), Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena M.","family":"Cocheme\u0301","sequence":"additional","affiliation":[{"name":"From the British Heart Foundation Glasgow Cardiovascular Research Centre (D.G., N.N.H., C.A.H., E.B., A.F.D.), Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom; Department of Chemistry (R.A.J.S.), University of Otago, Dunedin, New Zealand; Medical Research Council Mitochondrial Biology Unit (H.M.C., M.P.M.), Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Murphy","sequence":"additional","affiliation":[{"name":"From the British Heart Foundation Glasgow Cardiovascular Research Centre (D.G., N.N.H., C.A.H., E.B., A.F.D.), Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom; Department of Chemistry (R.A.J.S.), University of Otago, Dunedin, New Zealand; Medical Research Council Mitochondrial Biology Unit (H.M.C., M.P.M.), Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna F.","family":"Dominiczak","sequence":"additional","affiliation":[{"name":"From the British Heart Foundation Glasgow Cardiovascular Research Centre (D.G., N.N.H., C.A.H., E.B., A.F.D.), Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom; Department of Chemistry (R.A.J.S.), University of Otago, Dunedin, New Zealand; Medical Research Council Mitochondrial Biology Unit (H.M.C., M.P.M.), Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M501527200"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.051627098"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2005.02.014"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000248212.86638.e9"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj080362"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.0000149143.04821.eb"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20081386"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0921-8734(92)90021-G"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.105.7.849"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10541-005-0102-7"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj20020533"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(00)00161-1"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2004.03.016"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.0000238347.77590.c9"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00513.2006"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M210432200"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(99)00069-1"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.05-3718com"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbabio.2008.03.029"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20080063"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.47.120505.105110"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M009093200"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1042\/bst0311295"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2004.06.045"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M404003200"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M608268200"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0931245100"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2008.09.003"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.30.6.1517"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.33.6.1353"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(99)00146-7"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(00)00079-1"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.0000037063.90643.0b"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200402000-00017"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.0000154879.49245.39"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.37.2.529"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.28.5.898"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02512487"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.35.1.179"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.37.2.391"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-3084(71)90053-3"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.101.18.2206"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2006.01.008"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(99)00228-2"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.3048"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.26.3.452"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.0000261970.18328.1d"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvn280"},{"key":"e_1_3_2_49_2","first-page":"H2023","volume":"292","year":"2006","unstructured":"Zhang DX, Gutterman DD. Mitochondrial reactive oxygen species-mediated signalling in endothelial cells. Am J Heart Cell Physiol. 2006; 292: H2023\u2013H2031.","journal-title":"Am J Heart Cell Physiol"},{"key":"e_1_3_2_50_2","first-page":"1974","volume":"17","year":"2003","unstructured":"Jauslin ML, Meier T, Smith RAJ, Murphy MP. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J. 2003; 17: 1974\u20131978.","journal-title":"FASEB J"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.0000250430.62775.99"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1179\/135100007X200227"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.09.016"},{"key":"e_1_3_2_54_2","first-page":"A483","volume":"70","year":"2008","unstructured":"Snow BJ, Rolfe FL, Murphy MP, Smith RA, Lockhart MM, Frampton CM, Taylor KM. Phase II study of the mitochondrial antioxidant mitoquinone for Parkinson\u2019s disease. Neurology. 2008; 70: A483\u2013A484.","journal-title":"Neurology"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.109.130351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:25:16Z","timestamp":1715577916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.109.130351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.109.130351"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.109.130351","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1163206.623885","asserted-by":"object"}]},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"2009-02-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-06-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-07-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}